1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About ShockWave Medical Inc

Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Shockwave Medical aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which Shockwave Medical refers to as Intravascular Lithotripsy (IVL). IVL is a minimally invasive, easy-to-use and safe way to significantly improve patient outcomes.
Douglas Godshall

5403 Betsy Ross Dr
Santa Clara, California 95054
Phone: 15102794262


3 Beaten-Down Growth Stocks That Billionaires Are Buying With Both Hands | The Motley Fool
Nov 23, 2022 10:47am

Some of the world''s most successful investors can''t get enough of The Trade Desk, Shockwave Medical, and SoFi Technologies.

Source:The Motley Fool
Shockwave Medical to Participate in the Piper Sandler 34th Annual Healthcare Conference
Nov 22, 2022 13:30pm

SANTA CLARA, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company will be participating in the Piper Sandler 34th Annual Virtual Healthcare Conference, scheduled to be held from November 29 to December 1, 2022.

Is ShockWave Medical Inc. (SWAV) a threat to investors?
Nov 15, 2022 18:24pm

As of Monday, ShockWave Medical Inc.’s (NASDAQ:SWAV) stock closed at $243.19, down from $246.60 the previous day. While ShockWave Medical Inc. has underperformed by -1.38%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SWAV rose by 11.73%, with highs and lows ranging from $320.54 to $113.36, […]

Source:US Post News
The Battle of Fundamentals and Techniques: ShockWave Medical Inc. (SWAV)
Nov 08, 2022 19:48pm

ShockWave Medical Inc. (SWAV)’s stock has witnessed a price declined of -9.23% from the previous close with its current price standing at $251.82. Its current price is -21.44% under its 52-week high of $320.54 and 122.14% more than its 52-week low of $113.36. Based on the past 30-day period, the stock price is -22.60% below […]

Source:US Post News
Will ShockWave Medical (SWAV) Continue to Beat its Earnings Estimates?
Nov 08, 2022 15:12pm

Alger Capital, an investment management company, released its “Alger Small Cap Focus Fund” third quarter investor letter. A copy of the same can be downloaded here. In the third quarter, the fund outperformed the Russell 2000 Growth Index. Consumer discretionary and industrial sectors contributed to the fund’s relative performance in the quarter, while healthcare and energy […]

Source:Yahoo Finance
ShockWave Medical (SWAV) Q3 2022 Earnings Call Transcript
Nov 08, 2022 03:30am

SWAV earnings call for the period ending September 30, 2022.

Source:The Motley Fool
ShockWave Medical, Inc. (SWAV) Q3 2022 Earnings Call Transcript
Nov 08, 2022 03:25am

ShockWave Medical, Inc. (NASDAQ:NASDAQ:SWAV) Q3 2022 Earnings Conference Call November 07, 2022 04:30 PM ET Company Participants Debbie Kaster - Vice President, Investor Relations Doug…

Source:Seeking Alpha
Shockwave Medical Earnings, Revenue Beat in Q3 By Investing.com
Nov 07, 2022 21:31pm

Shockwave Medical Earnings, Revenue Beat in Q3

ShockWave Medical GAAP EPS of $0.92 beats by $0.24, revenue of $131.3M beats by $7.51M
Nov 07, 2022 21:12pm

ShockWave Medical press release (SWAV): Q3 GAAP EPS of $0.92 beats by $0.24.Revenue of $131.3M (+101.5% Y/Y) beats by $7.51M.Shares -6.3%.Cash, cash equivalents and…

Source:Seeking Alpha
Shockwave Medical Reports Third Quarter 2022 Financial Results
Nov 07, 2022 21:03pm

SANTA CLARA, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September 30, 2022.

Earnings Preview: ShockWave Medical
Nov 04, 2022 16:14pm

ShockWave Medical (NASDAQ: SWAV ) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here''s what investors need to know before the announcement. Analysts estimate that ShockWave Medical will report an earnings per share (EPS) of $0.67. ShockWave Medical bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for … Full story available on Benzinga.com

Investing in ShockWave Medical Inc. (SWAV) might be an excellent idea, but the stock is currently overvalued/undervalued
Oct 27, 2022 15:00pm

ShockWave Medical Inc. (NASDAQ:SWAV) marked $296.82 per share on Wednesday, up from a previous closing price of $295.31. While ShockWave Medical Inc. has overperformed by 0.51%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SWAV rose by 39.84%, with highs and lows ranging from $314.90 to […]

Source:US Post News
Should Investors Worry About ShockWave Medical Inc''s Insider Sells?
Oct 22, 2022 19:30pm

Related Stocks: SWAV ,

Shockwave Medical Announces Details for Conference Call Discussing Third Quarter 2022 Results
Oct 20, 2022 12:30pm

SANTA CLARA, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, will report financial results for the third quarter 2022 after market close on Monday, November 7, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

7 Little-Known Stocks With Millionaire-Maker Potential
Oct 14, 2022 15:34pm

Although, on the surface, everything looks gloomy now for stocks, one point that the bears are forgetting, I would argue, is that we live in an era of unprecedented technological advancement. Never before in the world has there simultaneously been so many new, highly impactful technologies –from artificial intelligence to connected cars to fintech to autonomous vehicles to automated retail checkout devices. As a result, there are a diversity of companies that are little known today but whose products will generate tremendous amounts of revenue in two or three years. And, of course, the shares of these companies will go up hundreds of percent along the way, making them great stocks to buy at this point. Let’s take a look at seven little-known stocks to buy that can make those who buy a few thousand dollars of their shares today, millionaires in a decade. ICAD iCAD $1.91 EMBK Embark $6.45 GEVO Gevo $2.10 SWAV Shockwave Medical $273.94 YETI YETI Holdings $30.65 ARRY Array Technologies $16.38 DV DoubleVerify $28.51 iCAD (ICAD) Source: shutterstock.com/Peshkova iCAD (NASDAQ: ICAD ) develops products that use artificial intelligence to detect cancer more effectively and efficiently than standard-of-care products.

IBD Stock Of The Day Shockwave Medical: Why ''Razor Blades, Not Razors'' Is Driving Massive Growth
Oct 06, 2022 16:56pm

IBD Stock Of The Day Shockwave Medical is cracking deeper into the calcium game, and taking SWAV stock to new highs.

Source:Investor''s Business Daily
The Short Case For ShockWave Medical (NASDAQ:SWAV)
Oct 05, 2022 13:49pm

ShockWave Medical is currently executing on all cylinders, but SWAV stock''s valuation has gotten excessive. Click here to read why.

Source:Seeking Alpha
Vertex Among 25 Market Leaders On The IBD Breakout Stocks Index
Oct 05, 2022 12:00pm

As the market shows signs of a rebound, Vertex, Enphase and Shockwave Medical are among 25 stocks to watch.

Source:Investor''s Business Daily
TISSIUM Appoints Sara Toyloy as Independent Board Member
Sep 26, 2022 10:00am

PARIS, FRANCE and BOSTON, MA / ACCESSWIRE / September 26, 2022 / TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has appointed Sara Toyloy as its fourth independent member of the Board of Directors. Ms. Toyloy has over 30 years of experience in the medical device industry. In 2020, she founded Fabrica Consulting LLC, a medical device consulting firm providing global regulatory and clinical trial strategies, where she currently serves as president. Prior to this, she was at Elixir Medical Corporation for nearly 12 years, where she held several executive positions including President of New Therapies and Chief Regulatory Officer and Executive Vice President of Regulatory, Clinical and Quality. She also served as Executive Vice President of Biosensors International Group, and Vice President of Regulatory and Clinical Affairs at Medtronic Vascular. Ms. Toyloy began her career at Guidant Corporation (acquired by Boston Scientific in 2006) where she held several key roles, ultimately serving as Guidant''s Director of Regulatory Affairs and Clinical Research.